Ironwood Pharmaceuticals (IRWD) Common Equity (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Common Equity across 17 years of filings, most recently posting -$161.8 million for Q2 2026.

• In Q2 2026, Common Equity rose 47.48% year-over-year to -$161.8 million; the TTM figure through Jun 2026 stood at -$161.8 million (up 47.48% YoY), while the FY2025 annual figure was -$261.8 million, up 13.11% from the prior year.
• Common Equity came in at -$161.8 million for Q2 2026 at Ironwood Pharmaceuticals, up from -$217.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $706.9 million in Q1 2023 to a low of -$346.8 million in Q2 2023.
• Average Common Equity over 5 years is -$46.1 million, with a median of -$282.7 million recorded in 2024.
• Year-over-year, Common Equity soared 369.89% in 2022 and sank 165.08% in 2023.
• Over 5 years, Common Equity stood at $652.4 million in 2022, then tumbled by 153.08% to -$346.3 million in 2023, then rose by 12.98% to -$301.3 million in 2024, then climbed by 13.11% to -$261.8 million in 2025, then surged by 38.19% to -$161.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$161.8 million in Q2 2026, -$217.1 million in Q1 2026, and -$261.8 million in Q4 2025.